Sharekhan's research report on Sanofi India
Sanofi reported strong results for Q1CY22 with operating margins expanding 139 bps y-o-y and PAT coming in ahead of estimates. Revenues de-grew by 2.5% yoy while the PAT was up 2.7% yoy. Sanofi has identified three growth areas, which include accelerating growth in the diabetology space, fortifying presence in established/top brands, and focusing on building brands in consumer products. High-growth visibility from the chronic space , strong, and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives for Sanofi.
We retain our Buy recommendation on Sanofi India (Sanofi) with an unchanged PT of Rs. 9,250.